Mo Yifei, Zhou Jian, Ma Xiaojing, Zhu Wei, Zhang Lei, Li Jie, Lu Jingyi, Hu Cheng, Bao Yuqian, Jia Weiping
Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Diab Vasc Dis Res. 2018 Sep;15(5):402-408. doi: 10.1177/1479164118778850. Epub 2018 May 31.
To examine the association between haemoglobin A1c variability and macrovascular complication in type 2 diabetes.
We retrospectively enrolled 5278 diabetes patients with no history of cardiovascular disease and atherosclerosis by ultrasound at their first visit to the hospital from 1999 to 2010. Patients had a median of 4 haemoglobin A1c (range = 3-9) measurements during follow-up. Average haemoglobin A1c and haemoglobin A1c variability were calculated as intra-individual mean, standard deviation, coefficient of variation and adjusted standard deviation. Cardiovascular disease events and ultrasound results were re-evaluated from the medical history at the end of the study.
A total of 972 patients had macrovascular complication. Compared to those without atherosclerosis/cardiovascular disease (n = 4306), haemoglobin A1c intra-individual mean and haemoglobin A1c variability levels were significantly higher in patients with macrovascular complication ( p < 0.001). Multivariable logistic regression analysis showed that haemoglobin A1c variability was associated with macrovascular complication. Moreover, 488 patients with only atherosclerosis had significantly higher haemoglobin A1c intra-individual mean and haemoglobin A1c variability values than those without atherosclerosis/cardiovascular disease ( p < 0.001), but in 484 patients with cardiovascular disease incidents, only higher haemoglobin A1c intra-individual mean level was found ( p = 0.004).
In Chinese type 2 diabetes, haemoglobin A1c variability was associated with macrovascular complication. Long-term stabilization of glucose is important in diabetes management, especially in the early stage of atherosclerosis.
探讨2型糖尿病患者糖化血红蛋白(HbA1c)变异性与大血管并发症之间的关联。
我们回顾性纳入了1999年至2010年首次来我院就诊、无心血管疾病史且经超声检查无动脉粥样硬化的5278例糖尿病患者。患者在随访期间糖化血红蛋白(HbA1c)测量值的中位数为4次(范围=3 - 9次)。计算平均糖化血红蛋白(HbA1c)和糖化血红蛋白(HbA1c)变异性,包括个体内均值、标准差、变异系数和校正标准差。在研究结束时,根据病史重新评估心血管疾病事件和超声检查结果。
共有972例患者发生大血管并发症。与无动脉粥样硬化/心血管疾病的患者(n = 4306)相比,发生大血管并发症的患者其个体内糖化血红蛋白(HbA1c)均值和糖化血红蛋白(HbA1c)变异性水平显著更高(p < 0.001)。多变量逻辑回归分析显示,糖化血红蛋白(HbA1c)变异性与大血管并发症相关。此外,仅患有动脉粥样硬化的488例患者,其个体内糖化血红蛋白(HbA1c)均值和糖化血红蛋白(HbA1c)变异性值显著高于无动脉粥样硬化/心血管疾病的患者(p < 0.001),但在发生心血管疾病事件的484例患者中,仅发现个体内糖化血红蛋白(HbA1c)均值较高(p = 0.004)。
在中国2型糖尿病患者中,糖化血红蛋白(HbA1c)变异性与大血管并发症相关。血糖的长期稳定在糖尿病管理中很重要,尤其是在动脉粥样硬化的早期阶段。